C-UZXSYuva Biosciences
AI platform, mitochondrial science, compound discovery
discoverydiscoveringsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-UZXS
C-UZXSC-UZXSAI platform, mitochondrial science, compound discovery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Yuva Biosciences AI platform, mitochondrial science, compound discovery
Yuva Biosciences describes itself as targeting aging and aging-related diseases through AI and mitochondrial science. Its MitoNova AI platform is optimized to discover compounds that improve mitochondrial health and is trained on years of in-house and partner testing. The site says products using Yuva Biosciences-discovered compounds, including Y100, are already on the market.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Yuva Biosciences — Early mechanism · Bottom quartile. Derived deterministically from 5 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic